Millennium Management LLC Acquires 432,503 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Millennium Management LLC lifted its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 113.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 813,031 shares of the company's stock after acquiring an additional 432,503 shares during the quarter. Millennium Management LLC owned approximately 0.31% of Autolus Therapeutics worth $2,829,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new position in shares of Autolus Therapeutics during the 1st quarter valued at approximately $78,765,000. Armistice Capital LLC lifted its holdings in Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock worth $21,750,000 after purchasing an additional 1,578,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company's stock worth $35,020,000 after purchasing an additional 2,487,778 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company's stock worth $14,964,000 after purchasing an additional 925,000 shares in the last quarter. Finally, Great Point Partners LLC lifted its holdings in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock worth $11,977,000 after purchasing an additional 2,275,000 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.70.

Autolus Therapeutics Price Performance

Shares of AUTL traded up $0.08 during mid-day trading on Tuesday, hitting $4.26. 674,883 shares of the stock were exchanged, compared to its average volume of 1,351,376. The company has a market cap of $1.13 billion, a PE ratio of -3.55 and a beta of 2.04. Autolus Therapeutics plc has a 52-week low of $2.21 and a 52-week high of $7.45. The firm has a 50-day moving average of $3.89 and a two-hundred day moving average of $4.13. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.